Gladstone spacer GICD
 
HOME
Annual Report [PDF]
Behavioral Laboratory
Directions and Parking
Lab Members
Links to Other Websites
More About Our Research
PPG
Publications
Training
  Contact Us

  
Gladstone Institutes Home  
Institute of
Cardiovascular Disease		 GICD
 
Institute of
Virology and
Immunology		 GIVI
 
Center for
Translational
Research		 CTR
University of California,
San Francisco		 UCSF
 
Supporting Gladstone
Publications
Original Articles (peer reviewed)
  1. Tamgüney G, Giles K, Glidden DV, Lessard P, Wille H, Tremblay P, Groth DF, Yehiely F, Korth C, Moore RC, Tatzelt J, Rubinstein E, Boucheix C, Yang X, Stanley P, Lisanti MP, Dwek RA, Rudd PM, Moskovitz J, Epstein CJ, Cruz TD, Kuziel WA, Maeda N, Sap J, Ashe KH, Carlson GA, Tesseur I, Wyss-Coray T, Mucke L, Weisgraber KH, Mahley RW, Cohen FE, Prusiner SB (2008) Genes contributing to prion pathogenesis. J. Gen. Virol. 89:1777-1788
  2. Meilandt WJ, Yu G.-Q, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K, Mucke L (2008) Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer’s disease. J. Neurosci. 28:5007-5017
  3. Scearce-Levie K, Roberson ED, Gerstein H, Cholfin J, Mandiyan VS, Shah NM, Rubenstein JLR, Mucke L (2008) Abnormal social behaviors in mice lacking Fgf17. Genes Brain Behav. 7:344–354.
  4. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliväli J, Lesné S, Ashe KH, Muchowski PJ, Mucke L (2007) Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282:23818–23828.
  5. Chin J, Massaro CM, Palop JJ, Thwin MT, Yu G.-Q, Bien-Ly N, Bender A, and Mucke L (2007) Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer’s disease. J. Neurosci. 27:2727–2733.
  6. deIpolyi AR, Rankin K, Mucke L, Miller B, Gorno-Tempini ML (2007) Spatial cognition and the human navigation network in AD and MCI. Neurology 69:986–997.
  7. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu G.-Q, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron 55:695–711.
  8. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng I, Wu T, Gerstein H, Yu G.-Q, Mucke L (2007) Reducing endogenous tau ameliorates Aβ-induced deficits in an Alzheimer’s disease mouse model. Science 316:750–754.
  9. 7:344–354.
  10. Choi D.-S, Wang D, Yu G.-Q, Zhu G, Kharazia VN, Paredes JP, Chang WS, Deitchman JK Mucke L, and Messing RO (2006) PKC epsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc. Natl. Acad Sci. USA 103:8215–8220.
  11. deIpolyi AR, Fang S, Palop JJ, Yu G.-Q Wang X, and Mucke L (2006) Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol. Aging 29:253-266
  12. Esposito L, Raber J, Kekonius L, Fan Y, Yu G.-Q, Bien-Ly N, Puoliväli J, Scearce-Levie K, Masliah E, and Mucke L (2006) Reduction in mitochondrial superoxide dismutase modulates Alzheimer’s disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J. Neurosci. 26:5167–5179.
  13. Morris R and Mucke L (2006) Alzheimer's disease: A needle from the haystack. Nature 440:284–285.
  14. Mueller-Steiner S, Zhou Y, Arai H, Sun B, Roberson ED, Chen J, Wang X, Yu G.-Q, Esposito L, Mucke L, and Gan L (2006) Anti-amyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer’s disease. Neuron 51:703–714.
  15. Palop JJ, Chin J, and Mucke L (2006) A network dysfunction perspective on neurodegenerative diseases. Nature 443:768–773.
  16. Roberson ED and Mucke L (2006) 100 years and counting: Prospects for defeating Alzheimer’s disease. Science 314:781–784.
  17. Roberson ED, Scearce-Levie K, Yan F, Wu T, Gerstein H, Yu G.-Q, Mucke L (2007) Reducing endogenous tau ameliorates Aκ-induced deficits in an Alzheimer’s disease mouse model. Science In Press
  18. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Van Can J, Lin AH, Crews L, Tremblay P, Matthews P, Mucke L, Masliah E, and Wyss-Coray T (2006) Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology. J. Clin. Invest. 116:3060–3069.
  19. Chen J, Zhou Y, Mueller-Steiner S, Chen L-F, Kwon H, Yi S, Mucke L, and Gan L (2005) SIRT1 protects against microglia-dependent beta amyloid toxicity through inhibiting NF-κB signaling. J. Biol Chem. 280:40364–40374.
  20. Palop JJ, Chin J, Bien-Ly N, Massaro C, Yeung BZ, Yu G-Q, and Mucke L (2005) Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J. Neurosci. 25:9686–9693.
  21. Chin J, Palop JJ, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, and Mucke L (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25:9694–9703.
  22. Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Esposito L, Mucke L, and Masliah E (2005) High β-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-β levels: Implications for the treatment of Alzheimer’s disease. J. Biol. Chem. 280:32957–32967.
  23. Cheng IH, Palop JJ, Esposito LA, Bien-ly N, Yan F, and Mucke L (2004) Aggresive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med.10:1190–1192.
  24. Esposito L, Gan L, Yu G-Q, Essrich C, and Mucke L (2004) Intracellularly generated amyloid-β peptides counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells. J. Neurochem. 91:1260–1274.
  25. Arrancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan Sf, Stern A, Ludy JS, Lue L-F, Walker DG, Roher A, Buttini M, Mucke L, Li W, Schmidt AM, Kindy M, Hyslop PA, Stern DM, and Yan SSD (2004) RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice. EMBO J. 23: 4096–4105.
  26. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu G-Q, Xu Q, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, and Huang Y (2004) Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice J. Neurosci. 24: 2527–2534.
  27. Chin J, Palop JJ, Yu G-Q, Kojima N, Masliah E, and Mucke L (2004) Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 24: 4692–4697.
  28. Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, and Mucke L (2003) Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer’s disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA 100: 9572–9577.
  29. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, and Huang Y (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer’s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. USA 100: 10966–10971.
  30. Buttini M, Yu G-Q, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, and Mucke L (2002) Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging and overexpression of Aβ but not on plaque formation. J. Neurosci. 22: 10539–10548.
  31. Raber J, LeFevour A, Buttini M, and Mucke L (2002) Androgens protect against ApoE4-induced cognitive deficits. J. Neurosci. 22: 5204–5209.
  32. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, and Mucke L (2001) β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc. Natl. Acad. Sci. USA 98: 12245–12250.
  33. Wyss-Coray T, Lin C, Yan F, Yu G-Q, Rohde M, McConlogue L, Masliah E, and Mucke L (2001) TGFβ1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat. Med.7: 612–618.
  34. Mucke L, Yu G-Q, McConlogue L, Rockenstein EM, Abraham CR, and Masliah E (2000) Astroglial expression of human α1-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice. Am. J. Pathol. 157: 2003–2010.
  35. Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, and McConlogue L (2000) High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci. 20: 4050–4058.
  36. Buttini M, Akeefe H, Lin C, Mahley RW, Pitas RE, Wyss-Coray T, and Mucke L (2000) Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience 97: 207–210.
  37. Raber J, Akana SF, Bhatnagar S, Dallman MF, Wong D, and Mucke L (2000) Hypothalamic-pituitary-adrenal dysfunction in Apoe – /– mice: Possible role in behavioral and metabolicalterations. J. Neurosci. 20: 2064–2071.
  38. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, and Mucke L (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 287: 1265–1269.
  39. Raber J, Wong D, Yu G-Q, Buttini M, Mahley RW, Pitas RE, and Mucke L (2000) Alzheimer’s disease: Apolipoprotein E and cognitive performance. Nature 404: 352–354.
  40. Wyss-Coray T, Lin C, Sanan DA, Mucke L, and Masliah E (2000) Chronic overproduction of transforming growth factor-β1 in astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Am. J. Pathol. 156: 139–150.
  41. D’Hooge R, Franck F, Mucke L, and De Deyn PP (1999) Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur. J. Neurosci. 11: 1–5.
  42. Huang F, Buttini M, Wyss-Coray T, McConlogue L, Kodama T, Pitas RE, and Mucke L (1999) Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am. J. Pathol. 155: 1741–1747.
  43. Sofroniew MV, Bush TG, Blumauer N, Kruger L, Mucke L and Johnson MH (1999) Genetically-targeted and conditionally-regulated ablation of astroglial cells in the central, enteric and peripheral nervous systems in adult transgenic mice. Brain Res. 835: 91–95.
  44. Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, Mucke L, Johnson MH, and Sofroniew MV (1999) Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23: 1–20.
  45. Xu X, Yang D, Wyss-Coray T, Yan J, Gan L, Sun Y,and Mucke L (1999) Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 96: 7547–7552.
  46. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, Mucke L, and Mahley RW (1999) Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: Isoform-specific effects on neurodegeneration. J. Neurosci. 19: 4867–4880.
  47. Hsia A, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K, Kholodenko D, Malenka R, Nicoll R, and Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc. Natl. Acad. Sci. USA 96: 3228–3233.
  48. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, and Mucke L (1998) Isoform-specific effects of human apolipoprotein E on brain function revealed in Apoe knockout mice–Increased susceptibility of females. Proc. Natl. Acad. Sci. USA 95: 10914–10919.
  49. Masliah E, Raber J, Alford M, Mallory M, Mattson MP, Yang D, Wong D, and Mucke L (1998) Amyloid protein precursor stimulates excitatory amino acid transport: Implications for roles in neuroprotection and pathogenesis. J. Biol. Chem. 273: 12548–12554.
  50. Krucker T, Toggas SM, Mucke L, and Siggins GR (1998) Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus. Neuroscience 83: 691–700.
  51. Buttini M, Westland CE, Masliah E, Yafeh AM, Wyss-Coray T, and Mucke L (1998) Novel role of human CD4 molecule identified in neurodegeneration. Nat. Med. 4: 441–446.
  52. Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, Johnson MH, and Sofroniew MV (1998) Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 93: 189–201.
  53. Xu X, Raber J, Yang D, Su B, and Mucke L (1997) Dynamic regulation of c-jun N-terminal kinase activity in mouse brain by environmental stimuli. Proc. Natl. Acad. Sci. USA 94: 12655–12660.
  54. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, and Mucke L (1997) Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer’s disease. Nature 389: 603–606.
  55. Wyss-Coray T, Borrow P, Brooker MJ, and Mucke L (1997) Astroglial overproduction of TGF-β1 enhances inflammatory central nervous system disease in transgenic mice. J. Neuroimmunol. 77: 45–50.
  56. Raeber AJ, Race RE, Brandner S, Priola SA, Sailer A, Bessen RA, Mucke L, Manson J, Aguzzi A, Oldstone MBA, Weissmann C, and Chesebro B (1997) Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J. 16: 6057–6065.
  57. Raber J, Chen S, Mucke L, and Feng L (1997) Corticotropin-releasing factor and adrenocorticotrophic hormone as potential central mediators of OB effects. J. Biol. Chem. 272: 15057–15060.
  58. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, and Mucke L (1997) Cellular signaling roles of TGFβ, TNFα and β APP in brain injury responses and Alzheimer’s disease. Brain Res. Rev. 23: 47–61.
  59. Masliah E, Westland CE, Rockenstein EM, Abraham CR, Mallory M, Veinberg I, Sheldon E, and Mucke L (1997) Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neuroscience 78: 135–146.
  60. Zhao J, Paganini L, Mucke L, Gordon M, Refolo L, Carman M, Sinha S, Oltersdorf T, Lieberburg I, and McConlogue L (1996)β-secretase processing of theβ-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes. J. Biol. Chem. 271: 31407–31411.
  61. Wyss-Coray T, Masliah E, Toggas SM, Rockenstein EM, Brooker MJ, Lee HS, and Mucke L (1996) Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1 gp120 transgenic mice and humans with HIV-1 encephalitis. J. Clin. Invest. 97: 789–798.
  62. Toggas SM, Masliah E, and Mucke L (1996) Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res. 706: 303–307.
  63. Raber J, Toggas SM, Lee S, Bloom FE, Epstein CJ, and Mucke L (1996) Central nervous system expression of HIV-1 gp120 activates the hypothalamic-pituitary-adrenal axis: Evidence for an involvement of NMDA receptors and nitric oxide synthase. Virology 226: 362–373.
  64. Mohajeri MH, Bartsch U, van der Putten H, Sansig G, Mucke L, and Schachner M (1996) Neurite outgrowth on non-permissive substrates in vitro is enhanced by ectopic expression of the neural adhesion molecule L1 by mouse astrocytes. Eur. J. Neurosci. 8: 1085–1097.
  65. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, and Games D (1996) Comparison of the neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer’s disease. J. Neurosci. 16: 5795–5811.
  66. D’Hooge R, Nagels G, Westland CE, Mucke L, and De Deyn PP (1996) Spatial learning deficit in mice expressing human 751-amino acid β-amyloid precursor protein. Neuroreport7: 2807–2811.
  67. Wyss-Coray T, Feng L, Masliah E, Ruppe MD, Lee HS, Toggas SM, Rockenstein EM, and Mucke L (1995) Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1. Am. J. Pathol. 147: 53–67.
  68. Verderber L, Johnson W, Mucke L, and Sarthy V (1995) Differential regulation of a GFAP-lacZ transgene in retinal astrocytes and Müller cells. Invest. Ophthalmol. Vis. Sci. 36:1137–1143.
  69. Rockenstein E, McConlogue L, Tan H, Gordon M, Power M, Masliah E, and Mucke L (1995) Levels and alternative splicing of amyloid β protein precursor (APP) transcripts in brains of transgenic mice and humans with Alzheimer’s disease. J. Biol. Chem. 270: 28257–28267.
  70. Rall GF, Mucke L, and Oldstone MBA (1995) Consequences of cytotoxic T lymphocyte interaction with MHC class I-expressing neurons in vivo. J. Exp. Med. 182: 1201–1212.
  71. Race RE, Priola SA, Bessen RA, Ernst D, Dockter J, Rall GF, Mucke L, Chesebro B, and Oldstone MBA (1995) Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron 15: 1183–1191.
  72. Mucke L, Abraham CR, Ruppe MD, Rockenstein EM, Toggas SM, Alford M, and Masliah E (1995) Protection against HIV-1 gp120-induced brain damage by neuronal expression of amyloid precursor protein. J. Exp. Med. 181: 1551–1556.
  73. Johnson WB, Ruppe MD, Rockenstein EM, Price J, Sarthy VP, Verderber LC, and Mucke L (1995) Indicator expression directed by regulatory sequences of the glial fibrillary acidic protein (GFAP) gene: In vivo comparison of distinct GFAP-lacZ transgenes. Glia 13: 174–184.
  74. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, and Penniman L (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373: 523–527.
  75. Borrow P, Cornell JL, Ruppe MD, and Mucke L (1995) Immunization-induced inflammatory infiltration of the CNS in transgenic mice expressing a foreign antigen in astrocytes. J. Neuroimmunol. 61: 133–149.
  76. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, and Mucke L (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367: 188–193.
  77. Rall GF, Mucke L, Nerenberg M, and Oldstone MBA (1994) A transgenic mouse model to assess the interaction of cytotoxic T lymphocytes with virally infected, class I MHC-expressing astrocytes. J. Neuroimmunol. 52: 61–68
  78. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, and Abraham CR (1994) Synaptotrophic effects of human amyloidβ protein precursor in the cortex of transgenic mice. Brain Res. 666: 151–167.
  79. Mucke L and Rockenstein EM (1993) Prolonged delivery of transgene products to specific brain regions by migratory astrocyte grafts. Transgenics 1: 3–9.
  80. Mucke L and Eddleston M (1993) Astrocytes in infectious and immune-mediated diseases of the central nervous system. FASEB J. 7: 1226–1232.
  81. Eddleston MP and Mucke L (1993) Molecular profile of reactive astrocytes–Implications for their role in neurologic disease.Neuroscience 54: 15–36.
  82. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA, and Mucke L (1993) Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. USA 90: 10061–10065.
  83. Abraham CR, Kanemaru K, and Mucke L (1993) Expression of cathepsin G-like and β1-antichymotrypsin-like proteins in reactive astrocytes. Brain Res. 621: 222–232.
  84. Mucke L and Oldstone MBA (1992) The expression of major histocompatibility complex (MHC) class I antigens in the brain differs markedly in acute and persistent infections with lymphocytic choriomeningitis virus (LCMV). J. Neuroimmunol. 36: 193–198.
  85. Mucke L, Oldstone MBA, Morris JC, and Nerenberg MI (1991) Rapid activation of astrocyte-specific expression of GFAP-lacZ transgene by focal injury. New Biol. 3: 465–474.
  86. Joly E, Mucke L, and Oldstone MBA (1991) Viral persistence in neurons explained by a lack of major histocompatibility class I expression. Science 253: 1283–1285.
  87. Ross ME, Evinger MJ, Hyman SE, Carroll JM, Mucke L, Comb M, Reis DJ, Joh TH, and Goodman HM (1990) Identification of a functional glucocorticoid response element in the phenylethanolamine N-methyltransferase promoter using fusion genes introduced into chromaffin cells in primary culture. J. Neurosci. 10: 520–530.
  88. Berger JR and Mucke L (1988) Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 38: 1060–1065.
  89. Schalling M, Dagerlind A, Brene S, Petterson R, Kvist S, Brownstein M, Hyman SE, Mucke L, Goodman HM, Joh TH, Goldstein M, and Hökfelt T (1987) Localization of mRNA for phenylethanolamine N-methyltransferase (PNMT) using in situ hybridization. Acta Physiol. Scand. 131: 631–632.
  90. Norita M, Mucke L, Benedek G, Albowitz B, Katoh Y, and Creutzfeldt OD (1986) Connections of the anterior ectosylvian visual area (AEV). Exp. Brain. Res. 62: 225–240.
  91. Mucke L, Norita M, Benedek G, and Creutzfeldt OD (1982) Physiologic and anatomic investigation of a visual cortical area situated in the ventral bank of the anterior ectosylvian sulcus of the cat. Exp. Brain. Res. 46: 1–11.

Other Publications

  1. Mucke L and Pitas R (2004) Food for thought: Essential fatty acid protects against neuronal deficits in transgenic mouse model of AD. Neuron 43: 596–599.
  2. Huang Y, Weisgraber KH, Mucke L, and Mahley RW (2003) Apolipoprotein E: Diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer’s disease. J. Mol. Neurosci. 23:189–204.
  3. Wyss-Coray T and Mucke L (2002) Inflammation in neurodegenerative disease – A double-edged sword. Neuron 35: 419–432.
  4. Raber J, LeFevour A, and Mucke L (2001) Androgen treatment reduces cognitive deficits in female apoE4 transgenic mice. In Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics. Iqbal K, Sisodia S, Winblad B (eds) John Wiley & Sons, Ltd., pp. 747–757.
  5. Wyss-Coray T and Mucke L (2000) Ibuprofen, inflammation and Alzheimer disease. Nat. Med. 6: 973–974.
  6. Wyss-Coray T, Lin C, Von Euw D, Masliah E, Mucke L, and Lacombe P (2000) Alzheimer’s disease-like cerebrovascular pathology in transforming growth factor-β1 transgenic mice and functional metabolic correlates. Ann. N.Y. Acad. Sci. 903: 317–323.
  7. Mucke L, Buttini M, Mahley RW, Pitas RE, Raber J, and Wyss-Coray T (2000) Contributions of the glial injury response to the multifactorial pathogenesis of Alzheimer’s disease. In Neuro-Immune Interactions in Neurologic Disorders. Patterson P, Kordon C, Christen Y (eds). Springer-Verlag, Berlin, pp. 19–33.
  8. Toggas SM and Mucke L (1998) Transgenic models to assess the pathogenic potential of viral products in HIV-1-associated CNS disease. In The Neurology of AIDS. Gendelman HE, Lipton S, Swindells S (eds). Chapman & Hall, New York. pp. 156–167.
  9. Mucke L and Buttini M (1998) Molecular basis of HIV-associated neurologic disease. In Molecular Neurology. Martin J (ed).Scientific American Medicine, New York, pp. 135–154.
  10. Toggas SM and Mucke L (1996) Transgenic models in the study of AIDS dementia complex. Curr. Top. Microbiol. Immunol. 206: 223–241.
  11. Masliah E, Ge N, and Mucke L (1996) Pathogenesis of HIV-1 associated neurodegeneration. Crit. Rev. Neurobiol. 10: 57–67.
  12. Mucke L, Abraham CR, and Masliah E (1996) Neurotrophic and neuroprotective effects of hAPP in transgenic mice. Ann. N.Y. Acad. Sci. 777: 82–89.
  13. Mucke L, Masliah E, and Campbell IL (1995) Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines. Curr. Top. Microbiol. Immunol. 202: 187–205.
  14. Masliah E, Mallory M, Alford M, Ge N, and Mucke L (1995) Abnormal synaptic regeneration in hAPP695 transgenic and ApoE knockout mice. In Research Advances in Alzheimer’s Disease and Related Disorders. Iqbal K, Mortimer J, Winblad B, Wisniewski H (eds). John Wiley & Sons, pp. 405–414.
  15. Lipton SA, Brenneman DE, Silverstein FS, Masliah E, and Mucke L (1995) Gp120 and neurotoxicity in vivo. Trends Pharmacol. Sci. 16: 122
  16. Mucke L (1993) Transgenic models to study diseases of the nervous system: an in vivo approach to dissect complex pathogenetic networks. In Symposium in Immunology II. Eibl MM, Huber C, Peter HH, Wahn U (eds). Springer-Verlag, Berlin, pp. 121–31.
  17. Masliah E, Ueda K, and Mucke L (1993) Pathophysiological basis of Alzheimer’s disease. In World Congress of Anatomic and Clinical Pathology. Santoscoy GG (ed). Moduzzi Editore, Bologna
  18. Bloom FE, Campbell IL, and Mucke L (eds) (1993) Molecular and cellular mechanisms of neural-immune interactions. Discussions in Neuroscience, Vol. IX, Nos. 3+4. Elsevier Science Publishers, Amsterdam
  19. Abraham CR, Razzaboni BL, Papastoitsis G, Picard E, Kanemaru K, Meckelein B, and Mucke L (1992) Purification and cloning of brain proteases capable of degrading theβ-amyloid precursor protein. Ann. N.Y. Acad. Sci. 674: 174–179.
  20. Benedek G, Mucke L, Norita M, Albowitz B, and Creutzfeldt OD (1988) Anterior ectosylvian visual area (AEV) of the cat: physiological properties. Prog. Brain. Res. 75: 245–255.
  21. Maciewicz R and Mucke L (1987) Principles of pain management. In Current Therapy in Neurological Disease-2. Bayless TM, Brain MC, Cherniack RM (eds). B.C. Decker, Inc., pp. 43–48
  22. Maciewicz R and Mucke L (1987) Principles of pain management. In Current Therapy in Internal Medicine. Bayless TM, Brain MC, Cherniack RM (eds). B.C. Decker, Inc., pp. 1248–1253.

TOP


Gladstone Home | Cardiovascular Disease | Virology and Immunology | Neurological Disease | Administration | UCSF  
Contact Webmaster | Copyright © The J. David Gladstone Institutes | CMS created by Altrue.com | Admin.